PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-24.88%
G&A reduction while CRVO shows 37.03% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Other expenses reduction while CRVO shows 100.00% growth. Joel Greenblatt would examine efficiency.
-27.70%
Operating expenses reduction while CRVO shows 251.41% growth. Joel Greenblatt would examine advantage.
-27.70%
Total costs reduction while CRVO shows 15.98% growth. Joel Greenblatt would examine advantage.
-8.45%
Interest expense reduction while CRVO shows 0.00% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
27.70%
EBITDA growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
27.70%
Operating income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-27.70%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
117.18%
Tax expense change of 117.18% while CRVO maintains burden. Bruce Berkowitz would investigate strategy.
-117.18%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-117.27%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-117.27%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.